Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Business Overview: The Company operates a telemedicine platform focusing on men's wellness products (ED, hair loss, testosterone, weight management) under brands such as Mango, Grow, Mojo, and Slim. It also markets FDA-approved oral testosterone (Prime) and has acquired intellectual property related to respiratory illness prevention and nutraceuticals. The Company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenues | $109,306 | $214,095 |
| Gross Profit | $62,064 | $147,398 |
| Operating Expenses | $4,915,253 | $2,515,015 |
| Net Loss | $(4,839,489) | $(2,367,617) |
| Loss Per Share (Basic/Diluted) | $(1.29) | $(1.50) |
| Cash and Equivalents (Ending) | $76,496 | $15,305 |
| Total Assets | $21,753,857 | $15,370,511 |
| Total Liabilities | $1,503,196 | $1,425,463 |
| Working Capital | $(1,326,544) | $(1,349,868) |
Note: Working Capital calculated as Total Current Assets ($176,652) minus Total Current Liabilities ($1,503,196).
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased by approximately 49% to $109,306, primarily attributed to transition and migration issues between the original and new telehealth platforms.
- Expense Surge: Total operating expenses nearly doubled to $4.9 million. Significant increases included:
- Investor Relations: Rose to $1.42 million (from $143,000) due to expanded public awareness efforts.
- General & Administrative: Increased to $1.54 million (from $772,000) driven by legal fees, technology development, and IP acquisition costs.
- Stock-Based Compensation: Increased to $1.05 million (from $454,000) due to greater use of equity incentives.
- Intangible Assets: Total assets increased significantly due to the capitalization of new Master Distribution Agreements (Dermytol and Diabetinol) and patent acquisitions, totaling over $21.5 million in non-current assets.
- Capital Structure: The Company completed a 1-for-15 reverse stock split in October 2024. During Q1 2025, the Company raised approximately $2.285 million through financing activities, including the sale of preferred stock, common stock, and warrant exercises.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing includes a "Going Concern" warning. With an accumulated deficit of $25.9 million and a working capital deficit, the Company states it will need to raise additional capital to fund operations for the next 12 months. There is no assurance such funding will be available on favorable terms.
- Strategic Acquisitions & Agreements:
- Entered into Master Distribution Agreements for Dermytol (skin brightening) and Diabetinol (blood glucose management), paying consideration primarily in common stock.
- Acquired intellectual property from Smokeless Technology Corp. for oral pouch delivery mechanisms.
- Legal Proceedings: Eli Lilly and Company filed a complaint alleging false advertising regarding the Company's "TRIM" product (oral dissolvable tirzepatide). The Company has removed the product from its website and is defending the matter. A settlement was reached in May 2025 with 1800 Diagonal Lending, LLC involving the issuance of stock.
- Related Party Transactions: Significant reliance on related parties, including the CEO's entities for pharmacy services (Epiq Scripts) and loans. The CEO recently received voting control (75.2%) of a subsidiary, Mango & Peaches Corp.
- Outlook: Management plans to continue marketing strategies, expand operations organically or via acquisition, and pursue an aggressive growth strategy pending funding. No specific financial guidance was provided.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $76,496 cash balance against the stated need for additional funding to survive the next 12 months.
- Dilution Risk: Review the terms of the Series B Convertible Preferred Stock (conversion price reduced to $1.50) and the $25 million Equity Line of Credit (ELOC), which pose significant dilution risks to common shareholders.
- Revenue Sustainability: Assess the impact of the telemedicine platform migration on future revenue recovery and the viability of new product lines (Dermytol, Diabetinol) which are not yet generating revenue.
- Legal Exposure: Monitor the status of the Eli Lilly litigation and the potential for further regulatory action regarding compounded products not approved by the FDA.
- Related Party Dependence: Evaluate the risks associated with the CEO's control over key operational subsidiaries (Mango & Peaches) and the compounding pharmacy (Epiq Scripts).